Verified

Improving the Quality and Standardization of Pneumococcal Diagnostic Pathways in Pediatric and Adult Populations

Pfizer

Streptococcus pneumoniae remains a major cause of respiratory infections, and its epidemiology continues to evolve due to serotype replacement, possible re-emergence of serotypes not controlled by indirect protection, and population aging. Suboptimal IPD surveillance in Italy likely underestimates disease burden yet reported incidence nearly doubled between 2022 and 2024. This initiative addresses a clear diagnostic performance gap by supporting quality improvement initiatives designed to optimize and standardize microbiological diagnostic pathways for pneumococcal disease. Consistent with Quality Improvement principles, projects should focus on implementation of evidence-based practices, optimization of diagnostic processes, improvement of data quality and completeness, and enhancement of collaboration between clinicians and laboratories in routine care settings.

Project Types and Area of Interest

This RFP seeks grant applications to improve the quality, standardization, and diagnostic yield of microbiological pathways for Streptococcus pneumoniae, thereby increasing the completeness and reliability of serotype surveillance data. Areas of interest include, but are not limited to:

a. Standardization of diagnostic pathways The primary objective of supported projects must be improvement of diagnostic processes, diagnostic performance, data capture, or implementation of best practices within participating institutions.

• Implementation and monitoring of standardized diagnostic bundles based on existing evidence and institutional best practices, including culture-based, antigen-based, and molecular diagnostic approaches where available.

• Optimization of sample management, including improved sample collection timing, standardized transport and storage procedures, and improvement of specimen management processes within routine clinical practice.

b. Integration of advanced diagnostics within routine clinical practice

• Improvement of data capture, completeness, and integration processes to support local surveillance and quality monitoring activities.

• Implementation and optimization of urinary antigen and serotype-specific tests already available for routine clinical use.

c. Education and training

• Training on diagnostic appropriateness and sample handling.

• Strengthening clinician/laboratory collaboration. d. Data integration

• Improvement of data capture, completeness, integration, and quality assurance processes to support ongoing institutional quality improvement and public health reporting activities.

Funding Range and Project Length

Individual projects requesting up to EUR 50,000.00 will be considered. Maximum project length is 2 years.

AI Based Application Success Predictor

Direct alignment with Pfizer’s therapeutic focus areas, such as:
- Oncology
- Vaccines
- Inflammation & Immunology
- Rare diseases
Projects addressing unmet medical needs are prioritized

👉 Misalignment with Pfizer’s current RFP (Request for Proposals) is a major rejection factor

🎯 2. Clear Impact on Patient Outcomes

Pfizer strongly favors proposals that demonstrate:

Improved patient care or clinical outcomes
Real-world applicability (not purely theoretical research)
Measurable endpoints (e.g., survival, quality of life, adherence)

👉 Compared to academic grants, practical impact is more heavily weighted

🧪 3. Robust Study Design & Methodology

Successful applications typically include:

Well-defined study protocols
Appropriate statistical plans
Feasible recruitment strategies

👉 Weak methodology is one of the most common rejection reasons

👩‍⚕️ 4. Investigator Credentials & Track Record

Proven publication record in the relevant field
Prior clinical research experience
Institutional support and infrastructure

👉 Early-career applicants can succeed, but usually with:

Strong mentorship
Clear feasibility

🏥 5. Institutional Capability

Access to:
- Patient population
- Clinical facilities
- Data management systems
Experience in conducting industry-sponsored trials

🤝 6. Independence & Transparency

For Pfizer grants (especially IIR):

Research must be investigator-initiated and independent
Clear disclosure of:
- Conflicts of interest
- Data ownership
Pfizer does not control study outcomes

💰 7. Realistic & Justified Budget

Budget must align with:
- Study scope
- Timeline
Overinflated or vague budgets reduce success chances

📑 8. Compliance with RFP Requirements

Strict adherence to:
- Proposal format
- Submission guidelines
- Required documentation

👉 Non-compliance can lead to automatic disqualification

🌍 9. Geographic & Strategic Priorities

Pfizer often prioritizes:
- Regions with high disease burden
- Projects aligned with global health strategies

⏳ 10. Feasibility & Timeline

Clearly achievable milestones
Realistic timelines
Defined deliverables

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with Pfizer RFP & therapeutic area
Patient-centered impact
Strong methodology

Moderate predictors:
4. Investigator track record
5. Institutional capability
6. Feasibility

Supporting factors:
7. Budget clarity
8. Compliance
9. Independence & transparency

💡 Insider Insight

Unlike Horizon Europe or NIH-type grants:

👉 Pfizer funding is more application-driven than theory-driven
👉 “Will this improve patient care soon?” is the central evaluation lens

Specialties

Infectious Diseases

Pediatrics

Others

Eligibility Requirements

• The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.

• The following public bodies may apply to hospitals, ASL, universities, IRCCS or accredited private clinics.

• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

• Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions / organizations / associations, are encouraged. Please note that all partners must have a relevant role and the requesting organization must have a key role in the project.

• The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).

• The Project Lead/PI must be an employee or contractor of the requesting organization.

• Requesting organization must be legally able to receive award funding directly from Pfizer LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer LLC may be subject to rescission.

Eligible Countries:

Italy

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type: Corporate/Non-Profit

Address: 66 Hudson Boulevard East, New York, NY 10001

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity